GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFMW) » Definitions » Accumulated other comprehensive income (loss)

Sunshine Biopharma (Sunshine Biopharma) Accumulated other comprehensive income (loss) : $0.15 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sunshine Biopharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Sunshine Biopharma's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was $0.15 Mil.

Sunshine Biopharma's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 ($0.21 Mil) to Dec. 2023 ($0.70 Mil) but then declined from Dec. 2023 ($0.70 Mil) to Mar. 2024 ($0.15 Mil).

Sunshine Biopharma's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 ($-0.02 Mil) to Dec. 2022 ($0.16 Mil) and increased from Dec. 2022 ($0.16 Mil) to Dec. 2023 ($0.70 Mil).

Sunshine Biopharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Sunshine Biopharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Accumulated other comprehensive income (loss) Chart

Sunshine Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.02 0.16 0.70

Sunshine Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.67 0.21 0.70 0.15

Sunshine Biopharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Sunshine Biopharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFMW) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
GHSI RLBD SHPH ACRX UNRV FLGC BUDZ CVSI DMK BFRI ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
SBFM:USA
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Website
https://www.sunshinebiopharma.com
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).